THE progressive arterial deterioration which accompanies ageing, may manifest itself in a variety of symptoms-all causing distress to the patient and increased problems for the physician. Elderly patients with advanced arteriosclerosis usually present one or more predominant signs or symptoms against a background of less obvious mental and physical impairment. Whilst treating a variety of peripheral vascular disorders in the elderly, with the spasmolytic vascodilator, Cyclospasmol, one observed that in addition to its control of the presenting complaint, there was frequently a remarkable improvement in the patient's general mental and physical well-being. Similar observations have been reported by a number of workers, including Ravina 1960 Ravina , 1964 van der Drift 1961; and Hornstein 1961 . A more detailed investigation of Cyclospasmol was made to see if these clinical impressions could be substantiated.
"Cyclospasmol is the mandelic ester of 3-5-5 trimethylcyclohexanol, and is a spasmolytic agent acting directly upon the smooth muscle of the vascular wall in a mode similar to that of papaverine, but with 5 times the activity" (Funcke 1951; Bijisma et al. 1956 ). The direct mechanism avoids autonomic effects or interference with circulating adrenaline. The drug has an extremely low toxicity. The approved generic name is cyclandelate. METHOD The effect of Cyclospasmol was studied in 27 patients aged from 52 and 82 (mean age 71.8 years), who showed some degree of senility, reflected in physical and mental symptoms. Each suffered several of the manifestations of vascular insufficiency, apart from peripheral complaints such as Raynaud's disease, intermittent claudication and leg ulcers. The vast majority of these patients also showed signs of cerebral vascular impairment. This wide variety of symptoms was also associated with a number of other severe concomitant lesions, some connected with vascular insufficiency and some not. These included 5 cases of coronary thrombosis, 3 cases of cerebral haemorrhage, and 2 cases of peptic ulceration. These conditions were all presented against a background of general senility.
At the commencement of this trial, the subjects were divided into two groups, the first group receiving Cyclospasmol and the second a placebo. The conditions of four patients in the control group deteriorated to such an extent that they were transferred to active treatment after one month. The three groups existing at the completion of the trial are shown' in table I. The duration of therapy was three months in each case. The patients received an initial dosage of 800 mg. daily for four weeks, followed by a reduction to 400 mg. daily for the remainder of the course. In some cases the higher dosage was reverted to if considered necessary. Treatment for concomitant disease was continued, and this included sedatives, soporifics, diabetic regimen, topical applications and specific dietary instructions. The subjects were examined at the commencement of the trial and at two weekly intervals until completion. RESULTS Taking the series as a whole, a number of significant points arise. In almost every patient some degree of hypertension was evident, and even on the highest dosage of Cyclospasmol (800 mg. daily) this was not significantly altered. In the series not one patient complained of adverse side effects and tolerance to the drug was excellent.
In the pro-forma clinical information sheet used for each patient, a number of specific headings were used to describe cerebral function as applied to thought processes and a number of headings to describe vestibular function. These are ischaemia and left bundle branch heart block were all present. Her B.P. was 165/85 with moderate arteriosclerosis. The peripheral and cerebral circulation were also impaired, with a large varicose ulcer, intermittent claudication, cold hands and feet, paraesthesia, and severe headache and vertigo. Treatment commenced with 800 mg. Cyclospasmol daily, reduced to 400 mg. after 1 month. At the end of 3 months, these latter symptoms had practically disappeared. Her hands and feet were only slightly cold, paraesthesia had gone, and the trophic ulcer was clearer. Intermittent claudication, restless legs, and the severe cramps had disappeared, and her cerebral signs of headache and vertigo had also gone; her blood pressure remained constant. An 82 year old man presented with vertigo and severe leg pain on walking. He was well nourished, with moderate arteriosclerosis, causing a number of cerebral and peripheral symptoms. He was slightly confused, memory loss was severe, and vertigo, intermittent claudication, cold hands and feet, paraesthesia and restless legs were also present. Improvement was slow in onset, but with Cyclospasmol his general condition gradually improved. Memory impairment for recent events decreased, enabling him to be much more useful domestically. His general restlessness was far less, and he slept better than for many years. He could once more dress, and eat, without assistance. Pain might still awaken him, but it soon disappeared on movement. His intermittent claudication was reduced from severe to slight, and he was delighted at being able to walk much further. Cold hands and feet, paraesthesia and cramp was better, in all a marked improvement in his condition.
DISCUSSION AND CONCLUSION
The general senile background present in these elderly patients is represented by a variety of minor signs and symptoms, each in itself often of small significance, but when grouped together, of major importance. Assessment cannot be by examination of each individual component of the senile background due to the variety of symptoms possible, and the fact that each patient may have a different combination.
The arguments for and against vasodilator therapy are many, but the absence of a simple method giving accurate and reproducible measurements of blood flow in particular tissues, makes substantiations of the various theories difficult. Without a simple objective test, the practising clinician must depend upon his impressions received from a number of semi-objective and subjective observations. Particularly when treating the elderly, the patient's own response and acceptance of the therapy is of prime importance. Therefore, the improvement in this aspect due to therapy must, in practice, be assessed by the general observations of the investigator and the others involved in the care of the patients.
A drug which is to be employed for long term medication should produce a minimum of side effects likely to cause distress. A highly significant factor in the success of the trial was the complete absence of variation in blood pressure, with its attendant risk of irreversible lesions in the cerebral and coronary arteries. Nor was any effect on the heart rate noticed. The importance of this aspect in the treatment of the elderly need not be stressed.
The 27 patients who entered the trial presented a total of 116 symptoms which were directly related to vascular insufficiency. Each subject suffered from at least two such symptoms.
When these results obtained in peripheral vascular disorders are studied, they are found to be very much in line with those reported by previous workers. Of patients with intermittent claudication 86 per cent. improved their walking distance on Cyclospasmol, whilst only 25 per cent. showed improvement on placebo. Similar results were recorded in patients showing Raynaud's phenomenon or suffering from cold hands and feet. My impressions would therefore tend to confirm those of Gillhespy (1959) , who considered Cyclospasmol to be one of the most effective drugs in the treatment of serious peripheral vascular lesions.
Of particular interest is the beneficial effect of Cyclospasmol where symptoms of coronary insufficiency exist. All the patients who entered the trial with anginal pain, showed marked improvement at the end, but it is significant that improvement did not become apparent until approximately two months' treatment had been completed. The beneficial effects produced by Cyclospasmol where coronary insufficiency exists coupled with an absence of tachycardial or blood pressure variations, makes it the ideal vasodilator for elderly patients with concomitant coronary lesions.
A significant benefit was obtained in those conditions due to cerebral insufficiency. Both confusion and memory loss showed marked improvement in those receiving Cyclospasmol therapy. Where the symptoms of vestibular insufficiency were present, similar results were obtained. The patient benefits greatly from the alleviation of these symptoms, which tend to cut him off from his normal activities. The effects of cerebral insufficiency, confusion, memory loss, and disorientation, seriously affect the ability of the patient to care for himself. They may lead to malnutrition, lack of hygiene, and failure to continue treatments as the patient pays less attention to himself and his surroundings. A vicious circle can develop.
A large number of patients entered the trial with symptoms of depressionwhether depression can be directly due to cerebral in,sufficiency is questionable.
A more valid explanation would be that the depression reflects the patient's own reaction to the ageing process and the resulting limitation which it puts on his activities, both physical and mental. In the majority of depressed patients, the depression was relieved by Cyclospasmol. It is logical that it is more positive therapy to remove or relieve the basic cause of the depression, than to administer potent anti-depressive agents. A significant number of patients who previously needed assistance both in dressing and eating, were again able to perform these simple functions, following Cyclospasmol treatment. Such improvement, coupled with relief of confusion and depression, improved sleep and less restlessness, gave marked benefits both to the patients and to those responsible for their welfare.
During the course of this trial, the overall improvement in the treated subjects was so apparent, that a feeling of envy and jealousy was engendered in those not included in the investigation. This reflects the overall effectiveness of Cyclospasmol in treating general senile problems.
It is my conclusion that Cyclospasmol, in addition to producing marked improvement in specific vascular disorders, at the same time has a beneficial effect on the general well-being of the elderly patient. I would echo the remarks of Ravina (1960) "the physical and mental well-being of the elderly is primarily dependent upon the integrity of the vascular system".
In assessing the results, significant improvements have been recorded in a large percentage of patients. Arteriosclerosis is a progressive condition and without treatment the patient's symptoms would normally worsen. Any patient whose regression is halted may be considered as having benefited from the treatment -apart from those showing improvement. Examination of Table II will show such cases in the active treatment group. In the placebo group the deterioration of conditions is apparent.
There can be no doubt that some of the improvement observed during the investigations was due to the increased medical attention which the patients received, but this is probably manifested in the various placebo effects noted but this must not be allowed to detract substantially from the very marked improvement shown by the large majority of the patients.
The marked absence of side-effects, and the long period of time necessary for the greatest benefit to be derived, demonstrate that Cyclospasmol is a spasmolytic of moderate but sustained activity. Maximum improvement usually becomes apparent within two months.
It is not the purpose of this investigation to discuss the mode of activity of Cyclospasmol, but the question may be raised whether the slow progressive action demonstrated in this trial reflects the promotion of collateral circulation, rather than the questionable dilation of atheromatous vessels. This might also explain the complete absence of hypotensive and tachycardial effects, the body having ample time to compensate for the vasodilation and increased collateral circulation.
-SUMMARY The spasmolytic vasodilator, Cyclospasmol, was compared with a placebo in a group of 27 patients showing the senile changes attendant in arteriosclerosis. A wide variety of symptoms were present. The dosage employed was Cyclospasmol 800 mg. daily for one month, reducing to 400 mg. daily for the remainder of the three month period of the trial.
1. There were no adverse side-effects reported; Cyclospasmol caused no variation in blood pressure. 2. Cyclospasmol produced improvement in 85 per cent. of symptoms due to vestibular insufficiency. 3. Eighty-three per cent. of peripheral vascular symptoms improved on Cyclospasmol. 4. Seven cases with anginal pain showed marked improvement after a maximum of 2 months' treatment with Cyclospasmol. 5. There was a significant improvement in the general mental and physical well-being of the majority of the patients receiving Cyclospasmol. 6. Cyclospasmol produced a slow but progressive improvement in peripheral, coronary and cerebral circulation. It may be necessary to continue treatment for a number of weeks before improvement is noticed.
